Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05651828 · ClinicalTrials.gov registry record · Early Phase 1
Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma
A Early Phase 1 study of Advanced Basal Cell Carcinoma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT05651828 is a Early Phase 1 study of Advanced Basal Cell Carcinoma that is actively recruiting participants, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 34 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05651828, a Early Phase 1 study of Advanced Basal Cell Carcinoma, is actively recruiting participants, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare how well tolerated and effective four different dosing schedules (two personalized, intermittent dosing schedules as compared to a fixed intermittent and continuous dosing regimen) work in people with advanced basal cell carcinoma.
Conditions Studied
Interventions
- DRUG Vismodegib 150 MG Oral Capsule
Study Locations (1)
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2023-03-23 |
| Est. Completion | 2029-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05651828
The ClinicalTrials.gov registry entry for NCT05651828 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Basal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Vismodegib 150 MG Oral Capsule is the first listed.
NCT05651828 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05651828 about?
NCT05651828 is a clinical study titled "Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma". The purpose of this study is to compare how well tolerated and effective four different dosing schedules (two personalized, intermittent dosing schedules as compared to a fixed intermittent and continuous dosing regimen) work in people with advanced basal cell carcinoma.
What is the current status of trial NCT05651828?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 34 participants. The study started on 2023-03-23. Estimated completion is 2029-12.
What conditions does trial NCT05651828 study?
This clinical trial studies the following conditions: Advanced Basal Cell Carcinoma.
What interventions are being tested in trial NCT05651828?
The interventions under investigation include: Vismodegib 150 MG Oral Capsule (DRUG).
Who is sponsoring clinical trial NCT05651828?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05651828 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.